Non-coding RNAs as therapeutic targets in hepatocellular cancer

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1073-1080

  Braconi, Chiara ^a   Patel, Tushar ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antagomirs; HCC; LNA antimiR; miRNA; Non coding RNA; Ultraconserved

Indexed keywords

AEG 35156; ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1C; EZN 2968; INTERLEUKIN 6; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 182; MICRORNA 221; MICRORNA 222; MICRORNA 26; MICRORNA 29; MIRAVIRSEN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; SORAFENIB; SPC 2649; SPC 2650; SPC 2651; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VIRUS VECTOR;

CELL CYCLE; CELL PROLIFERATION; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENE SILENCING; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

EID: 84872569720     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096112091073     Document Type: Review

References (54)

1. Yang, J. D.; Roberts, L. R. Hepatocellular carcinoma: A global view. Nat. Rev. Gastroenterol. Hepatol. 2010, 7 (8), 448-458.
2. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359 (4), 378-390.
3. Huarte, M.; Rinn, J. L. Large non-coding RNAs: missing links in cancer? Hum. Mol. Genet. 2010, 19 (R2), R152-161.
4. Louro, R.; Smirnova, A. S.; Verjovski-Almeida, S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics 2009, 93 (4), 291-298.
5. Mercer, T. R.; Dinger, M. E.; Mattick, J. S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 2009, 10 (3), 155-159.
6. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116 (2), 281-297.
7. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10 (10), 704-714.
8. Farazi, T. A.; Spitzer, J. I.; Morozov, P.; Tuschl, T. miRNAs in human cancer. J. Pathol. 2011, 223 (2), 102-115.
9. Heneghan, H. M.; Miller, N.; Kerin, M. J. MiRNAs as biomarkers and therapeutic targets in cancer. Curr. Opin. Pharmacol. 2010, 10 (5), 543-550.
10. Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S. S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; Gasparini, P.; Gonelli, A.; Costinean, S.; Acunzo, M.; Condorelli, G.; Croce, C. M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16 (6), 498-509.
11. Wong, Q. W.; Ching, A. K.; Chan, A. W.; Choy, K. W.; To, K. F.; Lai, P. B.; Wong, N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res. 2010, 16 (3), 867-875.
12. Fornari, F.; Gramantieri, L.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Giovannini, C.; Croce, C. M.; Bolondi, L.; Negrini, M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27 (43), 5651-5661.
13. Pineau, P.; Volinia, S.; McJunkin, K.; Marchio, A.; Battiston, C.; Terris, B.; Mazzaferro, V.; Lowe, S. W.; Croce, C. M.; Dejean, A. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107 (1), 264-269.
14. Gramantieri, L.; Fornari, F.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Croce, C. M.; Bolondi, L.; Negrini, M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 2009, 15 (16), 5073-5081.
15. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133 (2), 647-658.
16. Ji, J.; Shi, J.; Budhu, A.; Yu, Z.; Forgues, M.; Roessler, S.; Ambs, S.; Chen, Y.; Meltzer, P. S.; Croce, C. M.; Qin, L. X.; Man, K.; Lo, C. M.; Lee, J.; Ng, I. O.; Fan, J.; Tang, Z. Y.; Sun, H. C.; Wang, X. W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361 (15), 1437-1447.
17. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137 (6), 1005-1017.
18. Fornari, F.; Milazzo, M.; Chieco, P.; Negrini, M.; Calin, G. A.; Grazi, G. L.; Pollutri, D.; Croce, C. M.; Bolondi, L.; Gramantieri, L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70 (12), 5184-5193.
19. Henry, J. C.; Park, J. K.; Jiang, J.; Kim, J. H.; Nagorney, D. M.; Roberts, L. R.; Banerjee, S.; Schmittgen, T. D. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2010, 403 (1), 120-125.
20. Kim, S.; Lee, U. J.; Kim, M. N.; Lee, E. J.; Kim, J. Y.; Lee, M. Y.; Choung, S.; Kim, Y. J.; Choi, Y. C. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 2008, 283 (26), 18158-18166.
21. Bai, S.; Nasser, M. W.; Wang, B.; Hsu, S. H.; Datta, J.; Kutay, H.; Yadav, A.; Nuovo, G.; Kumar, P.; Ghoshal, K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009, 284 (46), 32015-32027.
22. Coulouarn, C.; Factor, V. M.; Andersen, J. B.; Durkin, M. E.; Thorgeirsson, S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28 (40), 3526-3536.
23. Gramantieri, L.; Ferracin, M.; Fornari, F.; Veronese, A.; Sabbioni, S.; Liu, C. G.; Calin, G. A.; Giovannini, C.; Ferrazzi, E.; Grazi, G. L.; Croce, C. M.; Bolondi, L.; Negrini, M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67 (13), 6092-6099.
24. Xiong, Y.; Fang, J. H.; Yun, J. P.; Yang, J.; Zhang, Y.; Jia, W. H.; Zhuang, S. M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51 (3), 836-845.
25. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; Volinia, S.; Guler, G.; Morrison, C. D.; Chan, K. K.; Marcucci, G.; Calin, G. A.; Huebner, K.; Croce, C. M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104 (40), 15805-15810.
26. Wong, C.M.; Wong, C.C.; Lee, J.M.; Fan, D.N.; Au, S.L.; Ng, I.O. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2011 doi: 10.1002/hep.25512. [Epub ahead of print].
27. Chen, P.J.; Yeh, S.H.; Liu, W.H., Lin, C.C.; Huang, H.C.; Chen, C.L.; Chen, D.S.; Chen, P.J. The androgen pathway stimulates microRNA-216a transcription to suppress the TSLC1 tumor suppressor gene in early hepatocarcinogenesis. Hepatology 2012 doi: 10.1002/hep.25695. [Epub ahead of print].
28. Petrelli, A.; Perra, A.; Schernhuber, K. Cargnelutti, M.; Salvi, A.; Migliore, C.; Ghiso, E.; Benetti, A.; Barlati, S.; Ledda-Columbano, G.M.; Portolani, N.; De Petro, G.; Columbano, A. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 2012 J doi: 10.1038/onc.2011.631. [Epub ahead of print]
29. Orom, U. A.; Derrien, T.; Beringer, M.; Gumireddy, K.; Gardini, A.; Bussotti, G.; Lai, F.; Zytnicki, M.; Notredame, C.; Huang, Q.; Guigo, R.; Shiekhattar, R. Long noncoding RNAs with enhancerlike function in human cells. Cell 2010, 143 (1), 46-58.
30. Braconi, C.; Valeri, N.; Kogure, T.; Gasparini, P.; Huang, N.; Nuovo, G. J.; Terracciano, L.; Croce, C. M.; Patel, T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 2011, 108 (2), 786-791.
31. Calin, G. A.; Liu, C. G.; Ferracin, M.; Hyslop, T.; Spizzo, R.; Sevignani, C.; Fabbri, M.; Cimmino, A.; Lee, E. J.; Wojcik, S. E.; Shimizu, M.; Tili, E.; Rossi, S.; Taccioli, C.; Pichiorri, F.; Liu, X.; Zupo, S.; Herlea, V.; Gramantieri, L.; Lanza, G.; Alder, H.; Rassenti, L.; Volinia, S.; Schmittgen, T. D.; Kipps, T. J.; Negrini, M.; Croce, C. M. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12 (3), 215-229.
32. Panzitt, K.; Tschernatsch, M. M.; Guelly, C.; Moustafa, T.; Stradner, M.; Strohmaier, H. M.; Buck, C. R.; Denk, H.; Schroeder, R.; Trauner, M.; Zatloukal, K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132 (1), 330-342.
33. Visone, R.; Russo, L.; Pallante, P.; De Martino, I.; Ferraro, A.; Leone, V.; Borbone, E.; Petrocca, F.; Alder, H.; Croce, C. M.; Fusco, A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer 2007, 14 (3), 791-798.
34. Li, J.; Wang, Y.; Yu, W.; Chen, J.; Luo, J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 2011, 406 (1), 70-73.
35. Esquela-Kerscher, A.; Trang, P.; Wiggins, J. F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J. B.; Brown, D.; Bader, A. G.; Slack, F. J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7 (6), 759-764.
36. Stephenson, M. L.; Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 1978, 75 (1), 285-288.
37. Soni, P. N.; Brown, D.; Saffie, R.; Savage, K.; Moore, D.; Gregoriadis, G.; Dusheiko, G. M. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 1998, 28 (5), 1402-1410.
38. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438 (7068), 685-689.
39. Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Levin, B.; Meruelo, D.; Osman, I.; Zavadil, J.; Marcusson, E. G.; Hernando, E. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011, 30 (12),1481-1488.
40. Park, J.K.; Kogure, T.; Nuovo, G.J.; Jiang, J.; He, L.; Kim, J.H.; Phelps, M.A.; Papenfuss, T.L.; Croce, C.M.; Patel, T.; Schmittgen, T.D. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011, 71 (24), 7608-7616.
41. Kasinski, A.L.; Slack, F.J. arresting the Culprit: targeted antagomir Delivery to Sequester oncogenic mir-221 in HCC. Molecular Therapy-Nucleic Acids 2012 doi:10.1038/mtna.2012.2; [Epub ahead of print].
42. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H. F.; Berger, U.; Gullans, S.; Kearney, P.; Sarnow, P.; Straarup, E. M.; Kauppinen, S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452 (7189), 896-899.
43. Jangra, R. K.; Yi, M.; Lemon, S. M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 2010, 84 (13), 6615-6625.
44. Lanford, R. E.; Hildebrandt-Eriksen, E. S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M. E.; Kauppinen, S.; Orum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327 (5962), 198-201.
45. Ebert, M. S.; Neilson, J. R.; Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4 (9), 721-726.
46. Grimm, D.; Streetz, K. L.; Jopling, C. L.; Storm, T. A.; Pandey, K.; Davis, C. R.; Marion, P.; Salazar, F.; Kay, M. A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441 (7092), 537-541.
47. Alexander, I. E.; Cunningham, S. C.; Logan, G. J.; Christodoulou, J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008, 15 (11), 831-839.
48. Annoni, A.; Brown, B. D.; Cantore, A.; Sergi, L. S.; Naldini, L.; Roncarolo, M. G. In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 2009, 114 (25), 5152-5161.
49. Heyes, J.; Palmer, L.; Bremner, K.; MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control Release 2005, 107 (2), 276-287.
50. Rozema, D. B.; Lewis, D. L.; Wakefield, D. H.; Wong, S. C.; Klein, J. J.; Roesch, P. L.; Bertin, S. L.; Reppen, T. W.; Chu, Q.; Blokhin, A. V.; Hagstrom, J. E.; Wolff, J. A. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 2007, 104 (32), 12982-12987.
51. Akinc, A.; Zumbuehl, A.; Goldberg, M.; Leshchiner, E. S.; Busini, V.; Hossain, N.; Bacallado, S. A.; Nguyen, D. N.; Fuller, J.; Alvarez, R.; Borodovsky, A.; Borland, T.; Constien, R.; de Fougerolles, A.; Dorkin, J. R.; Narayanannair Jayaprakash, K.; Jayaraman, M.; John, M.; Koteliansky, V.; Manoharan, M.; Nechev, L.; Qin, J.; Racie, T.; Raitcheva, D.; Rajeev, K. G.; Sah, D. W.; Soutschek, J.; Toudjarska, I.; Vornlocher, H. P.; Zimmermann, T. S.; Langer, R.; Anderson, D. G. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26 (5), 561-569.
52. Kim, S. I.; Shin, D.; Choi, T. H.; Lee, J. C.; Cheon, G. J.; Kim, K. Y.; Park, M.; Kim, M. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol. Ther. 2007, 15 (6), 1145-1152.
53. Nishina, K.; Unno, T.; Uno, Y.; Kubodera, T.; Kanouchi, T.; Mizusawa, H.; Yokota, T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 2008, 16 (4), 734-740.
54. Sato, A.; Takagi, M.; Shimamoto, A.; Kawakami, S.; Hashida, M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007, 28 (7), 1434-1442.